MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

Finally, Maviret, AbbVie’s hepatitis C drug, has made it through Canada’s approval process and has been listed for coverage by Ontario’s PharmaCare. We hope BC PharmaCare will also list it soon.

  • “MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)…
  • MAVIRET™ is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease”

https://www.newswire.ca/news-releases/abbvie-reaches-an-agreement-with-the-pan-canadian-pharmaceutical-alliance-pcpa-for-its-hepatitis-c-treatment-maviret-tm–822598355.html

See HepCBC’s patient-group recommendations about Maviret to CADTH and BC PharmaCare in 2017:

MAVIRET™ (CNW Group/AbbVie)